Apoptosis signal-regulating kinase inhibitor
The present invention relates to a compound of formula (I): The compound has apoptosis signal-regulating kinase (“ASK1”) inhibitory activity, and is thus useful in the treatment of diseases such as kidney disease, diabetic nephropathy and kidney fibrosis.
1. A tablet comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
2. The tablet of claim 1 , having 1 mg to 500 mg of the compound of formula (I).
3. The tablet of claim 1 , having 1 mg to 250 mg of the compound of formula (I).
4. A dosage unit comprising a compound of formula (I):
5. The dosage unit of claim 4 , having 1 mg to 500 mg of the compound of formula (I).
6. The dosage unit of claim 4 , having 1 mg to 250 mg of the compound of formula (I).
7. A method of treating liver fibrosis comprising administering to a patient in need thereof a tablet comprising a compound of formula (I):
or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
8. The method of claim 7 , wherein the tablet is administered in combination with at least one other therapeutic agent.
9. The method of claim 8 , wherein the at least one other therapeutic agent is selected from the group consisting of an angiotensin converting enzyme inhibitor, an angiotensin II receptor blocker, an antihypertensive agent, an antibiotic agent, an analgesic agent, an antidepressant agent, or an antianxiety agent.
10. The method of claim 7 , wherein the tablet comprises 1 mg to 500 mg of the compound of formula (I).
11. The method of claim 7 , wherein the tablet comprises 1 mg to 250 mg of the compound of formula (I).